We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision
News

Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision

Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision
News

Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Acrongenomics, Inc. and Molecular Vision, Ltd.- an Imperial Innovations spin-off company - have announced a joint collaboration intended to accelerate the development and commercialization of portable Point-of-Care (POC) diagnostic devices for personalized medical testing that will extend the tools available to the medical community.

The project outlined in the collaboration is intended to support the development of POC devices for on-the-spot diagnosis of diabetes management, STDs (Sexually Transmitted Diseases), cardiovascular diseases and substances of abuse, based on the BioLED technology developed by the Molecular Vision’s founders.

"With diagnostics and therapeutics converging in today’s healthcare market, Acrongenomics and Molecular Vision embark on a promising partnership to tackle the tough technical challenges associated with personalized medicine," said Constantine D. Poulios, president of Acrongenomics Inc.

"Through the combined strength of our teams, we will be able to deliver revolutionary POC diagnostics to market and provide sophisticated tools demanded by the global medical community."

"We look forward to working closely with Acrongenomics to develop a new generation of point-of-care diagnostic devices," said Donal Bradley co-founder of Molecular Vision Ltd.

"This collaboration enables us to progress towards our first products in a timely fashion."

Advertisement